It’s time for Congress to end Big Pharma’s war on generics 

Published June 4, 2026 11:00am ET



Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of patients, and the employers, unions, or programs such as Medicare that provide their drug coverage, the cost of some life-saving brand drugs is staggering.

The brand drug lobby tells us these sky-high prices are a necessity of the remarkable innovation we enjoy in healthcare. And make no mistake, that innovation is important. But as a growing amount of research shows, for many drugs this is an illusion. The high prices are part of Big Pharma’s masterclass in patent loopholes and legal maneuvering. They are waging a war on generic drug competition and artificially keeping prices too high for too long for too many.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.